Sotriffer C A, Ni H, McCammon J A
Department of Chemistry and Biochemistry, Howard Hughes Medical Institute, University of California, San Diego, La Jolla, California 92093-0365, USA.
J Med Chem. 2000 Nov 2;43(22):4109-17. doi: 10.1021/jm000194t.
Using the crystal structure of the first complex of the HIV-1 integrase catalytic core domain with an inhibitor bound to the active site, structural models for the interaction of various inhibitors with integrase were generated by computational docking. For the compound of the crystallographic study, binding modes unaffected by crystal packing have recently been proposed. Although a large search region was used for the docking simulations, the ligands investigated here are found to bind preferably in similar ways close to the active site. The binding site is formed by residues 64-67, 116, 148, 151-152, 155-156, and 159, as well as by residue 92 in case of the largest ligand of the series. The coherent picture of possible interactions of small-molecule inhibitors at the active site provides an improved basis for structure-based ligand design. The recurring motif of tight interaction with the two lysine residues 156 and 159 is suggested to be of prime importance.
利用人免疫缺陷病毒1型整合酶催化核心结构域与一种结合在活性位点的抑制剂形成的首个复合物的晶体结构,通过计算对接生成了各种抑制剂与整合酶相互作用的结构模型。对于晶体学研究的化合物,最近提出了不受晶体堆积影响的结合模式。尽管对接模拟使用了较大的搜索区域,但发现此处研究的配体倾向于以类似方式结合在靠近活性位点的位置。结合位点由64 - 67位、116位、148位、151 - 152位、155 - 156位和159位的残基形成,对于该系列中最大的配体,还由92位残基形成。小分子抑制剂在活性位点可能相互作用的连贯图景为基于结构的配体设计提供了更好的基础。与156位和159位两个赖氨酸残基紧密相互作用的重复基序被认为至关重要。